HeimAMPH • NASDAQ
add
Amphastar Pharmaceuticals Inc
24,86 $
Eftir lokun(4,58%)-1,14
23,72 $
Lokað: 16. maí, 18:43:06 GMT-4 · USD · NASDAQ · Lagalegir fyrirvarar
Við síðustu lokun
24,32 $
Dagbil
24,20 $ - 24,90 $
Árabil
22,64 $ - 53,96 $
Markaðsvirði
1,17 ma. USD
Meðalmagn
639,87 þ.
V/H-hlutf.
9,02
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | mar. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 170,53 m. | -0,76% |
Rekstrarkostnaður | 47,96 m. | 13,94% |
Nettótekjur | 25,28 m. | -41,44% |
Hagnaðarhlutfall | 14,83 | -40,99% |
Hagnaður á hvern hlut | 0,74 | -28,85% |
EBITDA | 50,90 m. | -16,54% |
Virkt skatthlutfall | 18,07% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | mar. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 236,88 m. | -18,19% |
Heildareignir | 1,63 ma. | 3,30% |
Heildarskuldir | 874,99 m. | -2,99% |
Eigið fé alls | 751,28 m. | — |
Útistandandi hlutabréf | 47,14 m. | — |
Eiginfjárgengi | 1,54 | — |
Arðsemi eigna | 5,82% | — |
Ávöxtun eigin fjár | 6,69% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | mar. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | 25,28 m. | -41,44% |
Handbært fé frá rekstri | 35,08 m. | -36,56% |
Reiðufé frá fjárfestingum | 10,48 m. | -31,21% |
Reiðufé frá fjármögnun | -14,50 m. | -6,80% |
Breyting á handbæru fé | 31,17 m. | -45,17% |
Frjálst peningaflæði | 16,94 m. | -57,15% |
Um
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.
In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.
In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn. Wikipedia
Stofnsett
1996
Höfuðstöðvar
Vefsvæði
Starfsfólk
2.028
